Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

ENDRA Life Sciences Inc. (NASDAQ:NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS^®), today announced the acceptance of a poster titled "Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity" for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego.

"This presentation highlights the potential of our TAEUS technology to obtain liver fat fraction measurements in patients with body mass index (BMI) exceeding 35, where accurate and reliable assessment of liver fat is challenging with existing point-of-care solutions. In extreme cases, TAEUS was able to obtain valid measurements of fat fraction in subjects with BMI exceeding 40, where the liver was more than 40mm below the skin surface. The subjects in this presentation were derived from a larger study comparing the performance of TAEUS to MRI measurements of fat fraction in the liver," stated Michael Thornton, Chief Technology Officer of ENDRA. "We are pleased this abstract was accepted for presentation at AASLD, the largest worldwide scientific conference for liver diseases. We are committed to submitting additional abstracts for presentation at medical and scientific meetings to create further awareness of the unique capabilities of our TAEUS technology in point-of-care applications."

Publication Number: 2089

Title: Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity

Presenter: Michael Thornton

Session: Diagnostics and Biomarkers - MASH

Date: November 16, 2024

Time: 8:00am – 5:00pm Pacific Standard Time

The poster will be available on the Research and Media section of ENDRA's website after the conference ends.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD) and metabolic dysfunction-associated steatohepatitis (MASH), chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as "approximate," "anticipate," "attempt," "believe," "could," "estimate," "expect," "forecast," "future," "goal," "hope," "intend," "may," "plan," "possible," "potential," "project," "seek," "should," "will," "would," or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and de novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA's ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA's ability to maintain compliance with Nasdaq listing standards; ENDRA's dependence on its senior management team; market acceptance of ENDRA's technology and the amount and nature of competition in its industry; ENDRA's ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112955229/en/